Patents by Inventor David T. Collin

David T. Collin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240123132
    Abstract: A drain cassette for a dialysis unit has a fluid channel between venous and arterial connection ports, and a valve may controllably open and close fluid communication between a drain outlet port and the venous connection port or the arterial connection port. A blood circuit assembly and drain cassette may be removable from the dialysis unit, e.g., by hand and without the use of tools. A blood circuit assembly may include a single, unitary member that defines portions of a pair of blood pumps, control valves, channels to accurately position flexible tubing for an occluder, an air trap support, and/or other portions of the assembly. A blood circuit assembly engagement device may assist with retaining a blood circuit assembly on the dialysis unit, and/or with removal of the assembly. An actuator may operate a retainer element and an ejector element that interact with the assembly.
    Type: Application
    Filed: December 22, 2023
    Publication date: April 18, 2024
    Applicant: DEKA Products Limited Partnership
    Inventors: Kevin L. Grant, Michael J. Wilt, Brian D. Tracey, Brett A. Rudolf, David E. Collins, Lisa A. Gustin, James D. Dale, Jesse T. Bodwell
  • Publication number: 20240067634
    Abstract: This disclosure relates generally to inhibitors of MHC-I downmodulation, and methods of treating or preventing an HIV infection by administering the inhibitors to a patient in need of treatment thereof.
    Type: Application
    Filed: December 16, 2021
    Publication date: February 29, 2024
    Inventors: David H. Sherman, Morgan T. McCauley, Nolan Carney, Andrew W. Robertson, Mark M. Painter, Kathleen L. Collins, Ashootosh Tripathi, Alanna R. Condren
  • Patent number: 5622720
    Abstract: The invention relates to a process for reducing the crystal size of ondansetron hydrochloride dihydrate produced by crystallization from solvent to a size which is suitable for effective distribution in a tablet blend, in particular 100% less that 250 .mu.m. The ondansetron hydrochloride dihydrate is desolvated by drying at elevated temperature and reduced or atmospheric pressure and is then rehydrated.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 22, 1997
    Assignee: Glaxo Group Limited
    Inventor: David T. Collin
  • Patent number: 5344658
    Abstract: The invention relates to a process for reducing the crystal size of ondansetron hydrochloride dihydrate produced by crystallisation from solvent to a size which is suitable for effective distribution in a tablet blend, in particular 100% less that 250 .mu.m. The ondansetron hydrochloride dihydrate is desolvated by drying at elevated temperature and reduced or atmospheric pressure and is then rehydrated.
    Type: Grant
    Filed: January 19, 1993
    Date of Patent: September 6, 1994
    Assignee: Glaxo Group Limited
    Inventor: David T. Collin